ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 950,17
0,11%
Dow Jones
44 544,66
-0,75%
DAX
21 732,05
0,01%
Brent Oil
76,385
0,00%
Bitcoin
100 727,02
-1,65%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. USOTC

  6. Astellas Pharma Inc (PK) (ALPMY) Cours

Astellas Pharma Inc (PK)

Astellas Pharma Inc (PK) (ALPMY)

USOTC
9,68
-0,21
(-2,12%)
Fermé 01 Février 10:00PM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
9,68
Prix Achat
9,53
Prix Vente
9,92
Volume échangé
94 828
9,68 Fourchette du Jour 9,756
9,05 Plage de 52 semaines 13,14
Cap du marché
17,518B
Clôture Veille
9,89
Ouverture
9,70
Dernière Transaction
114
@
9.68
Dernière heure de transaction
Volume financier
US$ 921 571
VWAP
9,7183
Volume moyen (3 m)
290 666
Actions en circulation
1 809 663 075
Rendement du Dividende
5.10%
Ratio Cours sur Bénéfices
1,00
Bénéfice par action (BPA)
9,42
Chiffre d'affairess
1,62T
Bénéfice net
17,05B

À propos de Astellas Pharma Inc (PK)

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Diversified
Site Web
www.astellas.com
Siège social
Chuo, Tokyo, Jpn
Fondé
1984
Astellas Pharma Inc (PK) est coté dans le secteur Pharmaceutical Preparations de la OTCMarkets avec le ticker ALPMY. Le dernier cours de clôture d'Astellas Pharma (PK) était de US$9,89. Au cours de la dernière année, les actions de Astellas Pharma (PK) ont été négociées dans une fourchette de prix de US$ 9,05 à US$ 13,14.

Astellas Pharma (PK) compte actuellement 1 809 663 075 actions en circulation. La capitalisation boursière d'Astellas Pharma (PK) est de US$17,90 milliard. Astellas Pharma (PK) a un ratio cours/bénéfice (ratio PE) de 1.00.

ALPMY Dernières nouvelles

Plus de nouvelles

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award

Astellas and The Chris Klug Foundation Announce Winners of the 2015 Bounce Back Award PR Newswire NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015 NORTHBROOK, Ill. and ASPEN, Colo., June 4, 2015...

04 Juin 2015
PR Newswire (US)

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Mee...

New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting PR Newswire TOKYO and NORTHBROOK, Ill., June 1, 2015 TOKYO and...

01 Juin 2015
PR Newswire (US)

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refr...

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability And Efficacy Data For ASP2215 In Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML) - Results from Phase 1/2 trial...

30 Mai 2015
PR Newswire (US)

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Tria...

Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial Data Presented in Plenary Session at AUA 2015 PR Newswire TOKYO and...

17 Mai 2015
PR Newswire (US)

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting

Astellas And Medivation Announce New Enzalutamide Data Presented At The 2015 American Urological Association Annual Meeting PR Newswire TOKYO and SAN FRANCISCO, May 17, 2015 TOKYO and SAN...

17 Mai 2015
PR Newswire (US)

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be...

Astellas Announces New Data in Advanced Prostate and Breast Cancers, Acute Myeloid Leukemia, and Lung and Renal Cancers To Be Presented at 2015 ASCO Annual Meeting PR Newswire NORTHBROOK, Ill...

14 Mai 2015
PR Newswire (US)

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting

Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting PR Newswire NORTHBROOK, Ill., May 5, 2015 NORTHBROOK, Ill., May 5, 2015 /PRNewswire/...

05 Mai 2015
PR Newswire (US)

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics

Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics Exclusive Collaboration Includes Option for Astellas to Acquire Potenza PR Newswire TOKYO and...

22 Avril 2015
PR Newswire (US)

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function

Astellas Appoints Shontelle Dodson to Lead Medical Excellence Function PR Newswire TOKYO, April 6, 2015 TOKYO, April 6, 2015 /PRNewswire/ -- Astellas ("Astellas,") (Tokyo: 4503) today announced...

06 Avril 2015
PR Newswire (US)

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia

MD Anderson, Astellas Pharma Sign Option Agreement for Monoclonal Antibody Drug Targeting Acute Myeloid Leukemia PR Newswire TOKYO and HOUSTON, April 3, 2015 TOKYO and HOUSTON, April 3, 2015...

03 Avril 2015
PR Newswire (US)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.293.088391906289.3910.139.051842249.7639615DR
40.0550.5714285714299.62510.139.052851239.59430554DR
12-1.4572-13.084078583511.137211.619.052906669.96559959DR
26-1.66-14.638447971811.3413.149.0518170110.52169253DR
52-1.89-16.335350043211.5713.149.0524595510.33425143DR
156-6.31-39.462163852415.9917.969.0517694812.25194567DR
260-8-45.248868778317.6818.479.0513799713.09504018DR

ALPMY - Frequently Asked Questions (FAQ)

What is the current Astellas Pharma (PK) share price?
The current share price of Astellas Pharma (PK) is US$ 9,68
How many Astellas Pharma (PK) shares are in issue?
Astellas Pharma (PK) has 1 809 663 075 shares in issue
What is the market cap of Astellas Pharma (PK)?
The market capitalisation of Astellas Pharma (PK) is USD 17,9B
What is the 1 year trading range for Astellas Pharma (PK) share price?
Astellas Pharma (PK) has traded in the range of US$ 9,05 to US$ 13,14 during the past year
What is the PE ratio of Astellas Pharma (PK)?
The price to earnings ratio of Astellas Pharma (PK) is 1
What is the cash to sales ratio of Astellas Pharma (PK)?
The cash to sales ratio of Astellas Pharma (PK) is 0,01
What is the reporting currency for Astellas Pharma (PK)?
Astellas Pharma (PK) reports financial results in JPY
What is the latest annual turnover for Astellas Pharma (PK)?
The latest annual turnover of Astellas Pharma (PK) is JPY 1,62T
What is the latest annual profit for Astellas Pharma (PK)?
The latest annual profit of Astellas Pharma (PK) is JPY 17,05B
What is the registered address of Astellas Pharma (PK)?
The registered address for Astellas Pharma (PK) is 2-5-1 NIHONBASHI-HONCHO, CHUO-KU, CHUO, TOKYO, 103-8411
What is the Astellas Pharma (PK) website address?
The website address for Astellas Pharma (PK) is www.astellas.com
Which industry sector does Astellas Pharma (PK) operate in?
Astellas Pharma (PK) operates in the PHARMACEUTICAL DIVERSIFIED sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NXGBNxGen Brands Inc (CE)
US$ 0,003
(299 900,00%)
180,55k
DOCKFBeyond Med Technologies Inc (PK)
US$ 0,055
(54 900,00%)
3,05k
SDCCQSmileDirectClub Inc (CE)
US$ 0,0004
(39 900,00%)
52,05k
LTFDLittlefield Corporation (CE)
US$ 0,1525
(38 025,00%)
240
SGMDSugarmade Inc (CE)
US$ 0,0003
(29 900,00%)
5,94k
RTNBroot9B Holdings Inc (CE)
US$ 0,000001
(-99,97%)
666
THMOThermoGenesis Holdings Inc (CE)
US$ 0,000001
(-99,86%)
250
DOMWFPrime Drink Group Corporation (PK)
US$ 0,0012
(-99,08%)
311,03k
TTCMTautachrome Inc (CE)
US$ 0,000001
(-99,00%)
125,07k
MITJFMint Corporation (CE)
US$ 0,0001
(-99,00%)
12k
HCMCHealthier Choices Management Corporation (PK)
US$ 0,000001
(0,00%)
316,07M
HMBLHUMBL Inc (PK)
US$ 0,0007
(0,00%)
218,85M
GRLFGreen Leaf Innovations Inc (PK)
US$ 0,00015
(-25,00%)
210,68M
RONNRonn Motor Group Inc (PK)
US$ 0,0003
(0,00%)
171,31M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0,00275
(-1,79%)
134,31M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

USOTC
ALPMY
Astellas Pharma (PK)
BIT
CAUT
Global X China Electric ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés

Supprimer les publicités

Inscrivez-vous pour une expérience sans publicité

Aucune publicité

Essayez maintenant

Conserver les annonces